Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
ZEVRA THERAPEUTICS, INC.
Bear Case (25th pct.)
0.6% vs price
Base Case (Median)
37.6% vs price
Bull Case (75th pct.)
76.9% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| PE Comparable | $21.11 | 110.0% | Medium (25%) |
| Graham Number | $7.44 | -26.0% | Medium (40%) |
| EV/EBITDA | $16.67 | 65.9% | Medium (20%) |
| EV/FCF | $11.00 | 9.4% | Medium (20%) |
Based on 4 out of 7 methods, ZVRA appears undervalued at the current price of $10.05. The base case fair value of $13.83 implies 37.6% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.